Clinical Trial Update: Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tafasitamab plus lenalidomide as first salvage therapy for residual large B-cell lymphoma is currently recruiting (sponsored by H. Lee …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Monjuvi (tafasitamab)
• Revlimid (lenalidomide)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Large B-cell Lymphoma | Phase 2 | Status: RECRUITING